A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
Study Details
Study Description
Brief Summary
A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
The study is being planned to evaluate long term safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD).
Total 1500 male and female patients with NAFLD with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Saroglitazar 4 mg tablets Oral (once daily ) during 364 days/52 weeks of treatment period. |
Drug: Saroglitazar
4 Mg Oral Tablet
|
Outcome Measures
Primary Outcome Measures
- Change in liver stiffness [Baseline to Week 52]
liver stiffness measurement performed by transient elastography
- Frequency and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) [Baseline to Week 52]
Secondary Outcome Measures
- Change in TG, HDL-C, LDL-C and non HDL-C levels [Baseline to Week 24 and Week 52]
- Change in serum ALT value [Baseline to Week 24 and Week 52]
- Change in serum AST value [Baseline to Week 24 and Week 52]
- Change in serum ALP value [Baseline to Week 24 and Week 52]
- Change in body weight [Baseline to Week 24 and Week 52]
- Change in BMI [Baseline to Week 24 and Week 52]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male and female patients aged ≥18 years
-
Patients who have been prescribed Saroglitazar for NAFLD will be included in this Phase 4 study (patients who use Saroglitazar for the first time)
-
Patients able to and willing to provide written informed consent and comply with the requirements of the study protocol
.
-
Patients with a prior documented diagnosis of NAFLD based on the AASLD criteria. NAFLD is defined either by previous histology or clinical imaging in individuals who consume little or no alcohol and do not have a cause for secondary hepatic steatosis or another cause of chronic liver disease. In addition, patients must have one of the following criteria to indicate ongoing NAFLD at screening:
-
Liver stiffness through transient elastography, an LSM ≥8 kPa OR
-
Serum ALT ≥45 U/L
Exclusion Criteria:
-
Consumption of alcohol for at least 90 consecutive days in last one year: >2 units of alcohol per day (>14 units per week) for males and >1 unit of alcohol per day (>7 units per week) for females. Note: 1 unit = 360 mL of beer, or 120 mL of wine, or 30 mL of spirits/hard liquor
-
History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and metabolic liver diseases) and haemochromatosis.
-
Patient has known documented cirrhosis, either based on clinical criteria or liver histology or imaging.
-
Contraindications to Saroglitazar or any disease conditions affecting the ability to evaluate the effects of Saroglitazar.
-
History or other evidences of severe illness or any other conditions that would make patient, in the opinion of the investigator, unsuitable for the study.
-
Any previous history of ascites, hepatic encephalopathy, oesophageal varices or admission/emergency department visit for hepatic decompensation.
-
Women of child bearing potential: inability or unwillingness to practice contraception for the duration of the study.
-
Pregnant or breast feeding females
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Zydus Lifesciences Limited
Investigators
- Study Chair: Dr. Deven Parmar, MD,FCP, Zydus Therapeutics Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SARO.21.003